Birchview Capital, LP — 13F Holdings & Portfolio
CIK 1618205 · latest 13F-HR filed 2026-08-14
Birchview Capital, LP manages $213.8M in 13F-reported U.S. long-equity assets across 73 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KLAC (25.18%), BMY (8.01%), LRCX (7.09%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 14 new positions, exited 15, added to 30, and trimmed 20.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
C/O BIRCHVIEW CAPITAL
BURLINGTON, VT 05401
$213.8M
Long-equity book
73
Distinct positions
2026-06-30
Filed 2026-08-14
+14 / −15 / ↑30 / ↓20
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- KLA CORPORATION$24.6M +83.9%
- LAM RESEARCH CORPORATION$7.5M +97.2%
- NEKTAR THERAPEUTICS$3.4M +153.5%
- CORCEPT THERAPEUTICS INC$3.1M +161.4%
- BIODESIX INC$2.3M +55.5%
Top Trims
- COMPASS THERAPEUTICS INC-$4.1M -52.7%
- STRUCTURE THERAPEUTICS INC-$3.5M -73.3%
- OCULAR THERAPEUTIX INC-$2.5M -92.5%
- COMPASS PATHWAYS LTD-$1.6M -79.5%
- PHATHOM PHARMACEUTICALS INC-$1.6M -72.5%
New Positions
- ABIVAX SA$2.3M
- VIR BIOTECHNOLOGY INC$2.2M
- BIOAGE LABS INC$1.7M
- NOVO NORDISK A/S$1.2M
- ADAGENE INC$1.0M
Exited Positions
- NOVOCURE LTD$2.2M
- ENGENE HOLDINGS INC$1.7M
- ULTRAGENYX PHARMACEUTICAL INC$1.3M
- KALVISTA PHARMACEUTICALS INC$1.1M
- VERASTEM INC$795.0K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KLA CORPORATION | KLAC | 482480100 | $53.8M | 25.18% | 178,471 | SH |
| 2 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $17.1M | 8.01% | 297,243 | SH |
| 3 | LAM RESEARCH CORPORATION | LRCX | 512807306 | $15.2M | 7.09% | 35,000 | SH |
| 4 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $6.7M | 3.11% | 666,196 | SH |
| 5 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $6.5M | 3.05% | 385,400 | SH |
| 6 | BIODESIX INC | BDSX | 09075X108 | $6.5M | 3.02% | 286,804 | SH |
| 7 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $5.8M | 2.73% | 178,110 | SH |
| 8 | OVINTIV INC | OVV | 69047Q102 | $5.7M | 2.65% | 107,500 | SH |
| 9 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $5.7M | 2.64% | 81,000 | SH |
| 10 | CORCEPT THERAPEUTICS INC | CORT | 218352102 | $5.0M | 2.33% | 57,200 | SH |
| 11 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $4.6M | 2.14% | 27,190 | SH |
| 12 | PROTHENA CORP PLC | PRTA | G72800108 | $4.4M | 2.06% | 449,019 | SH |
| 13 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $4.3M | 2.02% | 171,000 | SH |
| 14 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $4.3M | 2.01% | 35,018 | SH |
| 15 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $3.7M | 1.72% | 1,675,000 | SH |
| 16 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $2.8M | 1.32% | 408,100 | SH |
| 17 | ALKERMES PLC | ALKS | G01767105 | $2.6M | 1.23% | 50,000 | SH |
| 18 | HALOZYME THERAPEUTICS INC | HALO | 40637H109 | $2.6M | 1.22% | 33,251 | SH |
| 19 | CELLDEX THERAPEUTICS INC | CLDX | 15117B202 | $2.6M | 1.22% | 69,900 | SH |
| 20 | CYTOKINETICS INC | CYTK | 23282W605 | $2.6M | 1.20% | 30,000 | SH |
| 21 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $2.5M | 1.16% | 199,000 | SH |
| 22 | VERA THERAPEUTICS INC | VERA | 92337R101 | $2.5M | 1.16% | 57,758 | SH |
| 23 | UNITED THERAPEUTICS CORP | UTHR | 91307C102 | $2.4M | 1.14% | 4,506 | SH |
| 24 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $2.4M | 1.11% | 93,601 | SH |
| 25 | UNIQURE NV | QURE | N90064101 | $2.3M | 1.09% | 50,697 | SH |
| 26 | PACIFIC BIOSCIENCES OF CALIFORNIA INC | PACB | 69404D108 | $2.3M | 1.06% | 1,350,000 | SH |
| 27 | ABIVAX SA | ABVX | 00370M103 | $2.3M | 1.06% | 17,000 | SH |
| 28 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $2.2M | 1.05% | 220,000 | SH |
| 29 | BIOGEN INC | BIIB | 09062X103 | $1.9M | 0.91% | 9,000 | SH |
| 30 | EQT CORPORATION | EQT | 26884L109 | $1.8M | 0.86% | 34,619 | SH |
| 31 | BIOAGE LABS INC | BIOA | 09077V100 | $1.7M | 0.79% | 69,000 | SH |
| 32 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $1.6M | 0.77% | 29,000 | SH |
| 33 | QUIDELORTHO CORP | — | 74838J101 | $1.6M | 0.73% | 89,377 | SH |
| 34 | AXSOME THERAPEUTICS INC | AXSM | 05464T104 | $1.5M | 0.69% | 6,000 | SH |
| 35 | FOGHORN THERAPEUTICS INC | FHTX | 344174107 | $1.4M | 0.64% | 281,937 | SH |
| 36 | BICYCLE THERAPEUTICS PLC | BCYC | 088786108 | $1.3M | 0.62% | 313,616 | SH |
| 37 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $1.3M | 0.60% | 24,000 | SH |
| 38 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $1.3M | 0.59% | 21,032 | SH |
| 39 | NOVO NORDISK A/S | NVO | 670100205 | $1.2M | 0.54% | 24,000 | SH |
| 40 | FREEPORT-MCMORAN CL-B | FCX | 35671D857 | $1.1M | 0.53% | 18,035 | SH |
| 41 | IMMUNOME INC | IMNM | 45257U108 | $1.1M | 0.50% | 50,000 | SH |
| 42 | PHARVARIS N V | PHVS | N69605108 | $1.0M | 0.48% | 29,847 | SH |
| 43 | HARROW HEALTH INC | HROW | 415858109 | $1.0M | 0.48% | 24,000 | SH |
| 44 | ADAGENE INC | ADAG | 005329107 | $1.0M | 0.47% | 240,000 | SH |
| 45 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $940.8K | 0.44% | 20,000 | SH |
| 46 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $782.0K | 0.37% | 71,218 | SH |
| 47 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $651.0K | 0.30% | 8,741 | SH |
| 48 | 4D MOLECULAR THERAPEUTICS INC | FDMT | 35104E100 | $645.1K | 0.30% | 48,505 | SH |
| 49 | UROGEN PHARMA LTD | URGN | M96088105 | $606.7K | 0.28% | 16,487 | SH |
| 50 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $596.8K | 0.28% | 55,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $213.8M | 73 | 0001618205-26-000003 |
| 2026-03-31 | 2026-05-15 | $175.7M | 73 | 0001618205-26-000002 |
| 2025-12-31 | 2026-02-13 | $170.8M | 68 | 0001618205-26-000001 |
| 2025-09-30 | 2025-11-13 | $132.4M | 69 | 0001618205-25-000011 |